Overview

Hp129 Xenon Imaging and BOS in Lung Transplantation

Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The research is being conducted to develop new imaging methods that are sufficiently sensitive to allow for early diagnosis of BOS, a chronic allograft rejection affecting 50-60% of lung transplanted recipients who survive 5 years after transplant. Although lung transplantation has evolved into an effective therapeutic option for a large number of pediatric patients with end-stage pulmonary disease, long-term survival after lung transplantation is far worse than after the transplantation of other solid organs. This research may improve patient outcomes through earlier diagnosis of changes leading to BOS by obtaining image guided research biopsies of transplanted lung. Biopsies may be used for future research of ex vivo biomarkers of BOS and in the development of treatments through future clinical trials.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Treatments:
Xenon